
About Piramal Pharma Solutions
Piramal Pharma Solutions is a publicly listed company based in Mumbai (India) founded in 1988. It serves as a contract manufacturer of pharmaceutical products for industry partners. It operates on a B2B model. The company has 5,480 employees. Piramal Pharma Solutions has completed 1 acquisition, including Hemmo Pharmaceuticals. Its website piramalpharmasolutions.com draws about 16 thousand monthly visits. Its Indian entity Piramal Pharma Limited reported revenue of βΉ9,161 Cr. Its focus areas include Healthcare, Pharmaceuticals, Manufacturing and Contract Production. Its competitors include Syngene, Piramal Group and Panacea Biotec; 1 of its 3 listed competitors has raised funding.
Company details
Piramal Pharma Solutions, founded in 1988 in Mumbai, India, focuses on providing healthcare solutions, producing pharmaceutical products, producing manufactured goods, and contract production. Serves as a contract manufacturer of pharmaceutical products for industry partners. The company is dedicated to excellence, innovation, and customer satisfaction, ensuring sustainable practices and long-term success in its sectors.
- Headquarters Mumbai, India
- Employees 5,480
- Stage Public
- SectorsIndustrial Goods & Manufacturing
- Emailβ’β’β’β’β’β’β’β’
- Website piramalpharmasolutions.com
- Social LinkedIn X Facebook YouTube
- Legal Name Piramal Pharma Ltd
- Date of Incorporation 04 Mar, 2020
- Jurisdiction Mumbai, Maharashtra, India
- Market Cap₹31,906 Cr
PPLPHARMA · NSE
- Share Price₹239.30
-0.15% today
- Revenue₹8,869 Cr
FY 2025-26 · -3.1% YoY
- EBITDA₹704 Cr
Margin 7.9%
- Net Profit−₹312 Cr
FY 2025-26 · -451.5% YoY
- ROE-3.8%
ROCE 2.5%
- Debt / Equity0.65
Interest cover -267.9x
- Employee Count5,480
- Investments & Acquisitions
Associated legal entities of Piramal Pharma Solutions
Piramal Pharma Solutions operates through Piramal Pharma Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Piramal Pharma Limited Listed CIN L24297MH2020PLC338592 | Active | 04 Mar 2020 | Mumbai, Maharashtra | ₹9,161 Cr | 3,851 | 12 | View details |
Apps and channels of Piramal Pharma Solutions
its YouTube channel Piramal Pharma Solutions has 9.09K subscribers and 30 videos.
Videos from Piramal Pharma Solutions
The most watched videos on Piramal Pharma Solutions's YouTube channel, Piramal Pharma Solutions (9.09K subscribers). Click a video to play it here.
More on Piramal Pharma Solutions.
Board of directors of Piramal Pharma Limited (Piramal Pharma Solutions)
Piramal Pharma Limited is the primary company behind Piramal Pharma Solutions. The board of Piramal Pharma Limited currently have 10 directors; the longest-serving is Peter D Deyoung, appointed in 2020. 2 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Peter D Deyoung DIN 07152550 | Whole-time director | 04 Mar 2020 | 6 yrs 8 mo | Piramal Pharma Limited |
| Nandini Ajay Piramal DIN 00286092 | Whole-time director | 04 Mar 2020 | 6 yrs 8 mo | Piramal Pharma Limited |
| Jairaj Manohar Purandare DIN 00159886 | Director | 09 Feb 2021 | 5 yrs 9 mo | Piramal Pharma Limited |
| Vivek Valsaraj DIN 06970246 | Whole-time director | 09 Feb 2022 | 4 yrs 9 mo | Piramal Pharma Limited |
| Sridhar Gorthi DIN 00035824 | Director | 30 Mar 2022 | 4 yrs 7 mo | Piramal Pharma Limited |
| Peter Andrew Stevenson DIN 09544706 | Director | 30 Mar 2022 | 4 yrs 7 mo | Piramal Pharma Limited |
| Vibha Paul Rishi DIN 05180796 | Director | 30 Aug 2022 | 4 yrs 2 mo | Piramal Pharma Limited |
| Nathalie Ann Leitch DIN 09557042 | Director | 28 Jan 2025 | 1 yr 9 mo | Piramal Pharma Limited |
| Amit Jain DIN 06917608 | Director | 14 May 2025 | 1 yr 6 mo | Piramal Pharma Limited |
| Amit Soni DIN 05111144 | Director | 09 Feb 2026 | 9 mo | Piramal Pharma Limited |
People of Piramal Pharma Solutions
51 people are tracked at Piramal Pharma Solutions (29 in leadership, 1 in board & advisors, 21 in team); the tracked headcount is 5,480.
| Name | Role | Group |
|---|---|---|
Michael Teague | Executive VP Global Operations at Piramal Critical Care Inc. | Leadership |
Christopher Leahy | Senior Vice President, Finance | Leadership |
Satyajit Tillu | Senior General Manager & Site Head | Leadership |
Susie Hodgson | Director Of Finance And Procurement | Leadership |
Debashish Chakravorty | Executive Vice President, India Formulations | Leadership |
Stuart Needleman | Chief Commercial Officer & Chief Patient Centricity Officer | Leadership |
Sujatha Kumar | General Manager L & D Global Pharna | Leadership |
Yogita Karakkadavath | Chief Manager - Corporate IP | Leadership |
Deepika Maskara | Global Head - Total Rewards And Corporate HR Head | Leadership |
| Executive Director & CEO | Leadership | |
Ravindra Pawar | Deputy Chief Manager | Leadership |
Anil Jaiswal | Head Of Human Resources | Leadership |
John Nause | Director, International Compliance/chief Compliance Officer | Leadership |
Anagha Deshpande | Vice President Finance & IT | Leadership |
Abhishek Fanse | Deputy Chief Manager - Human Resources And Administration | Leadership |
Ca Neelam Valani | Chief Manager Finance | Leadership |
Puneet Rajput | Chief Human Resources Officer | Leadership |
Swapnil Thakkar | Head Of Contract Manufacturing & Procurement | Leadership |
Girish Guna | Head - Indirect Tax | Leadership |
Manish Punjabi | Head - Learning & Development And Campus Talent Management | Leadership |
31 more people are available in the full profile.
Complete people profiles for Piramal Pharma Solutions
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Piramal Pharma Solutions
Piramal Pharma Solutions is a publicly listed company on the NSE with ticker symbol PPLPHARMA in India, operating in the Pharmaceuticals sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- Listed onNSE: PPLPHARMA
- Listed entityPiramal Pharma Limited
- Exchange sectorPharmaceuticals
Financials of Piramal Pharma Solutions
Exchange-reported figures of Piramal Pharma Limited, the listed company behind Piramal Pharma Solutions (NSE: PPLPHARMA).
Financial Highlights
FY 2025-26 Β· ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 8,869 | 9,151 | 8,171 | 7,082 | 6,559 | 6,315 |
| Revenue growth | -3.1% | +12.0% | +15.4% | +8.0% | +3.9% | - |
| EBITDA | 704 | 1,445 | 1,133 | 621 | 935 | 1,428 |
| EBITDA margin | +7.9% | +15.8% | +13.9% | +8.8% | +14.3% | +22.6% |
| Profit before tax | (176) | 415 | 179 | (120) | 485 | 949 |
| Net profit | (312) | 88.82 | 15.83 | (186) | 384 | 818 |
| Net profit margin | -3.5% | +1.0% | +0.2% | -2.6% | +5.9% | +13.0% |
| EPS (βΉ) | (2.46) | 0.69 | 0.13 | (1.56) | 3.17 | 8.40 |
| Balance sheet | ||||||
| Total assets | 14,088 | 13,206 | 12,822 | 12,612 | 10,991 | 8,780 |
| Net worth | 8,163 | 8,125 | 7,911 | 6,774 | 6,697 | 5,605 |
| Total debt | 5,675 | 4,856 | 4,710 | 5,637 | 4,128 | 3,025 |
| Cash & bank | 1,224 | 501 | 483 | 308 | 329 | 406 |
| Net working capital | 3,541 | 3,554 | 3,059 | 2,717 | 2,403 | 1,751 |
| Cash flow | ||||||
| Cash from operations | 1,653 | 892 | 1,005 | 484 | 766 | 598 |
| Cash from investing | (820) | (488) | (416) | (1,334) | (1,737) | (4,464) |
| Cash from financing | (38.98) | (441) | (422) | 818 | 794 | 3,977 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2,617 | 2,270 | 2,752 | 2,140 | 2,044 | 1,934 | 2,754 | 2,204 |
| Revenue growth (YoY) | +28.1% | +17.4% | -0.1% | -2.9% | -8.8% | -0.9% | - | - |
| Other income | 53.67 | 109 | 59.63 | 53.50 | 80.39 | 97.71 | 58.25 | 29.18 |
| EBITDA | 349 | 195 | 285 | 155 | 159 | 107 | 561 | 338 |
| EBITDA margin | +13.3% | +8.6% | +10.3% | +7.2% | +7.8% | +5.5% | +20.4% | +15.3% |
| Depreciation | 233 | 224 | 218 | 213 | 203 | 197 | 243 | 197 |
| Interest | 87.63 | 88.08 | 82.99 | 89.24 | 82.42 | 86.15 | 104 | 103 |
| Profit before tax | 81.63 | (7.46) | 43.00 | (93.86) | (46.18) | (79.02) | 273 | 66.80 |
| Tax | 76.60 | 61.93 | 51.83 | 42.33 | 53.04 | 2.68 | 119 | 63.12 |
| Net profit | 5.03 | (69.39) | (8.83) | (136) | (99.22) | (81.70) | 154 | 3.68 |
| EPS (βΉ) | 0.04 | (0.52) | (0.07) | (1.03) | (0.75) | (0.62) | 1.16 | 0.03 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 4,782 | 5,286 | 4,390 | 3,443 | 3,340 | 2,939 |
| Revenue growth | -9.5% | +20.4% | +27.5% | +3.1% | +13.7% | - |
| EBITDA | 549 | 1,040 | 618 | 90.57 | 460 | 619 |
| EBITDA margin | +11.5% | +19.7% | +14.1% | +2.6% | +13.8% | +21.1% |
| Profit before tax | 877 | 911 | 508 | 124 | 462 | 687 |
| Net profit | 768 | 689 | 388 | 72.64 | 378 | 556 |
| Net profit margin | +16.1% | +13.0% | +8.8% | +2.1% | +11.3% | +18.9% |
| EPS (βΉ) | 5.27 | 5.22 | 2.96 | 0.58 | 3.10 | 5.75 |
| Balance sheet | ||||||
| Total assets | 9,022 | 8,744 | 7,921 | 6,936 | 6,300 | 4,281 |
| Net worth | 8,141 | 7,453 | 6,712 | 5,262 | 5,123 | 4,101 |
| Total debt | 786 | 1,243 | 1,177 | 1,649 | 1,164 | 174 |
| Cash & bank | 574 | 178 | 242 | 64.16 | 137 | 152 |
| Net working capital | 1,842 | 2,101 | 1,797 | 1,337 | 1,166 | 463 |
| Cash flow | ||||||
| Cash from operations | 1,328 | 549 | 358 | 71.52 | 249 | 34.72 |
| Cash from investing | (318) | (552) | (635) | (435) | (1,165) | (4,383) |
| Cash from financing | (615) | (61.74) | 451 | 290 | 896 | 4,494 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,345 | 1,125 | 1,489 | 1,196 | 1,127 | 970 | 1,690 | 1,248 |
| Revenue growth (YoY) | +19.4% | +16.0% | -11.9% | -4.2% | -12.2% | -8.8% | - | - |
| Other income | 138 | 115 | 184 | 96.15 | 202 | 181 | 39.51 | 24.70 |
| Total expenses | 1,174 | 1,008 | 1,251 | 1,056 | 1,000 | 926 | 1,273 | 1,029 |
| EBITDA | 172 | 117 | 238 | 140 | 127 | 44.33 | 417 | 219 |
| EBITDA margin | +12.7% | +10.4% | +16.0% | +11.7% | +11.3% | +4.6% | +24.7% | +17.6% |
| Depreciation | 67.56 | 65.73 | 70.12 | 64.69 | 61.25 | 59.44 | 61.17 | 55.46 |
| Interest | 17.27 | 16.36 | 19.50 | 16.84 | 20.38 | 23.23 | 30.56 | 29.17 |
| Profit before tax | 225 | 149 | 332 | 155 | 247 | 143 | 364 | 159 |
| Tax | 53.86 | 36.00 | 70.22 | 26.02 | 51.08 | 29.44 | 87.09 | 40.61 |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2,617 | 2,270 | 2,752 | 2,140 | 2,044 | 1,934 | 2,754 | 2,204 |
| Revenue growth (YoY) | +28.1% | +17.4% | -0.1% | -2.9% | -8.8% | -0.9% | - | - |
| Other income | 53.67 | 109 | 59.63 | 53.50 | 80.39 | 97.71 | 58.25 | 29.18 |
| EBITDA | 349 | 195 | 285 | 155 | 159 | 107 | 561 | 338 |
| EBITDA margin | +13.3% | +8.6% | +10.3% | +7.2% | +7.8% | +5.5% | +20.4% | +15.3% |
| Depreciation | 233 | 224 | 218 | 213 | 203 | 197 | 243 | 197 |
| Interest | 87.63 | 88.08 | 82.99 | 89.24 | 82.42 | 86.15 | 104 | 103 |
| Profit before tax | 81.63 | (7.46) | 43.00 | (93.86) | (46.18) | (79.02) | 273 | 66.80 |
| Tax | 76.60 | 61.93 | 51.83 | 42.33 | 53.04 | 2.68 | 119 | 63.12 |
| Net profit | 5.03 | (69.39) | (8.83) | (136) | (99.22) | (81.70) | 154 | 3.68 |
| EPS (βΉ) | 0.04 | (0.52) | (0.07) | (1.03) | (0.75) | (0.62) | 1.16 | 0.03 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Revenue | 8,869 | 9,151 | 8,171 | 7,082 | 6,559 | 6,315 |
| Revenue growth | -3.1% | +12.0% | +15.4% | +8.0% | +3.9% | - |
| Other income | 292 | 208 | 235 | 279 | 335 | 230 |
| Total expenses | 8,165 | 7,706 | 7,038 | 6,460 | 5,625 | 4,887 |
| Employee cost | 2,416 | 2,307 | 2,030 | 1,896 | 1,589 | 1,468 |
| EBITDA | 704 | 1,445 | 1,133 | 621 | 935 | 1,428 |
| EBITDA margin | +7.9% | +15.8% | +13.9% | +8.8% | +14.3% | +22.6% |
| Depreciation | 831 | 816 | 741 | 677 | 586 | 545 |
| Interest | 341 | 422 | 448 | 344 | 198 | 163 |
| Profit before tax | (176) | 415 | 179 | (120) | 485 | 949 |
| Tax | 150 | 324 | 161 | 66.31 | 109 | 114 |
| Net profit | (312) | 88.82 | 15.83 | (186) | 384 | 818 |
| Net profit margin | -3.5% | +1.0% | +0.2% | -2.6% | +5.9% | +13.0% |
| EPS (βΉ) | (2.46) | 0.69 | 0.13 | (1.56) | 3.17 | 8.40 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Equity & liabilities | ||||||
| Share capital | 1,327 | 1,324 | 1,323 | 1,193 | 1,186 | 995 |
| Reserves & surplus | 6,835 | 6,801 | 6,588 | 5,580 | 5,511 | 4,610 |
| Shareholders' funds (net worth) | 8,163 | 8,125 | 7,911 | 6,774 | 6,697 | 5,605 |
| Minority interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Secured loans | 5,470 | 4,590 | 4,536 | 5,497 | 3,981 | 2,601 |
| Unsecured loans | 204 | 266 | 174 | 140 | 146 | 424 |
| Total debt | 5,675 | 4,856 | 4,710 | 5,637 | 4,128 | 3,025 |
| Total liabilities | 14,088 | 13,206 | 12,822 | 12,612 | 10,991 | 8,780 |
| Assets | ||||||
| Gross block | 14,829 | 13,077 | 12,099 | 10,842 | 9,510 | 8,153 |
| Net block | 8,684 | 8,133 | 7,990 | 7,469 | 6,879 | 6,105 |
| Capital work in progress | 1,100 | 977 | 1,116 | 1,419 | 1,172 | 627 |
| Investments | 437 | 291 | 385 | 639 | 267 | 123 |
| Inventories | 3,064 | 2,313 | 2,176 | 1,681 | 1,389 | 1,232 |
| Sundry debtors | 2,158 | 2,350 | 2,134 | 1,799 | 1,785 | 1,575 |
| Cash & bank balances | 1,224 | 501 | 483 | 308 | 329 | 406 |
| Loans & advances | 614 | 614 | 527 | 620 | 514 | 436 |
| Total current assets | 7,060 | 5,777 | 5,320 | 4,408 | 4,017 | 3,649 |
| Total current liabilities | 3,519 | 2,223 | 2,261 | 1,691 | 1,614 | 1,898 |
| Net working capital | 3,541 | 3,554 | 3,059 | 2,717 | 2,403 | 1,751 |
| Total assets | 14,088 | 13,206 | 12,822 | 12,612 | 10,991 | 8,780 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Opening cash | 182 | 219 | 53.23 | 85.18 | 262 | 152 |
| Net cash from operating activities | 1,653 | 892 | 1,005 | 484 | 766 | 598 |
| Net cash from investing activities | (820) | (488) | (416) | (1,334) | (1,737) | (4,464) |
| Net cash from financing activities | (38.98) | (441) | (422) | 818 | 794 | 3,977 |
| Net change in cash | 794 | (36.87) | 166 | (31.95) | (177) | 110 |
| Closing cash | 1,224 | 501 | 483 | 308 | 329 | 406 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Growth | ||||||
| Sales growth | -3.1% | +12.0% | +15.4% | +8.0% | +3.9% | - |
| EBITDA growth | -51.3% | +27.5% | +82.4% | -33.5% | -34.6% | - |
| PBT growth | - | +131.3% | +9998.0% | - | -48.9% | +9997.0% |
| Net income growth | -451.5% | +461.1% | +108.5% | -148.4% | -53.0% | - |
| Revenue CAGR (3Y) | +7.8% | +11.7% | +9.0% | - | - | - |
| EBITDA CAGR (3Y) | +4.3% | +15.6% | -7.4% | - | - | - |
| Profitability & leverage | ||||||
| Net income margin | -3.7% | +1.0% | +0.2% | -2.6% | +5.7% | +13.2% |
| Return on capital employed | +2.5% | +6.4% | +5.4% | +1.9% | +6.9% | +12.7% |
| Return on net worth | -3.8% | +1.1% | +0.2% | -2.8% | +6.1% | +14.9% |
| Debt / equity | 0.65 | 0.60 | 0.70 | 0.72 | 0.58 | 0.54 |
| Long-term debt / equity | 0.48 | 0.37 | 0.41 | 0.46 | 0.42 | 0.43 |
| Interest cover | -267.95 | 67.08 | 114.15 | -621.15 | 56.90 | 18.51 |
| Efficiency & per share | ||||||
| Fixed asset turnover | 0.64 | 0.73 | 0.71 | 0.70 | 0.74 | 0.77 |
| Inventory turnover | 3.30 | 4.08 | 4.24 | 4.61 | 5.01 | 5.13 |
| Debtors turnover | 3.94 | 4.08 | 4.15 | 3.95 | 3.90 | 4.01 |
| EPS (βΉ) | (2.46) | 0.69 | 0.13 | (1.56) | 3.17 | 8.40 |
| Dividend per share (βΉ) | 0.00 | 0.14 | 0.11 | 0.00 | 0.56 | 0.00 |
| Book value per share (βΉ) | 61.50 | 61.35 | 59.80 | 56.76 | 56.47 | 56.35 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,345 | 1,125 | 1,489 | 1,196 | 1,127 | 970 | 1,690 | 1,248 |
| Revenue growth (YoY) | +19.4% | +16.0% | -11.9% | -4.2% | -12.2% | -8.8% | - | - |
| Other income | 138 | 115 | 184 | 96.15 | 202 | 181 | 39.51 | 24.70 |
| Total expenses | 1,174 | 1,008 | 1,251 | 1,056 | 1,000 | 926 | 1,273 | 1,029 |
| EBITDA | 172 | 117 | 238 | 140 | 127 | 44.33 | 417 | 219 |
| EBITDA margin | +12.7% | +10.4% | +16.0% | +11.7% | +11.3% | +4.6% | +24.7% | +17.6% |
| Depreciation | 67.56 | 65.73 | 70.12 | 64.69 | 61.25 | 59.44 | 61.17 | 55.46 |
| Interest | 17.27 | 16.36 | 19.50 | 16.84 | 20.38 | 23.23 | 30.56 | 29.17 |
| Profit before tax | 225 | 149 | 332 | 155 | 247 | 143 | 364 | 159 |
| Tax | 53.86 | 36.00 | 70.22 | 26.02 | 51.08 | 29.44 | 87.09 | 40.61 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Revenue | 4,782 | 5,286 | 4,390 | 3,443 | 3,340 | 2,939 |
| Revenue growth | -9.5% | +20.4% | +27.5% | +3.1% | +13.7% | - |
| Other income | 663 | 207 | 202 | 341 | 225 | 216 |
| Total expenses | 4,233 | 4,245 | 3,772 | 3,353 | 2,880 | 2,320 |
| Employee cost | 745 | 736 | 614 | 548 | 448 | 395 |
| EBITDA | 549 | 1,040 | 618 | 90.57 | 460 | 619 |
| EBITDA margin | +11.5% | +19.7% | +14.1% | +2.6% | +13.8% | +21.1% |
| Depreciation | 256 | 222 | 205 | 192 | 165 | 144 |
| Interest | 79.95 | 115 | 107 | 116 | 57.29 | 4.71 |
| Profit before tax | 877 | 911 | 508 | 124 | 462 | 687 |
| Tax | 177 | 220 | 116 | 54.19 | 94.79 | 115 |
| Net profit | 768 | 689 | 388 | 72.64 | 378 | 556 |
| Net profit margin | +16.1% | +13.0% | +8.8% | +2.1% | +11.3% | +18.9% |
| EPS (βΉ) | 5.27 | 5.22 | 2.96 | 0.58 | 3.10 | 5.75 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Equity & liabilities | ||||||
| Share capital | 1,327 | 1,324 | 1,323 | 1,193 | 1,186 | 995 |
| Reserves & surplus | 6,814 | 6,128 | 5,389 | 4,068 | 3,937 | 3,106 |
| Shareholders' funds (net worth) | 8,141 | 7,453 | 6,712 | 5,262 | 5,123 | 4,101 |
| Secured loans | 421 | 1,009 | 896 | 1,313 | 1,154 | 90.20 |
| Unsecured loans | 365 | 234 | 281 | 336 | 10.69 | 84.06 |
| Total debt | 786 | 1,243 | 1,177 | 1,649 | 1,164 | 174 |
| Total liabilities | 9,022 | 8,744 | 7,921 | 6,936 | 6,300 | 4,281 |
| Assets | ||||||
| Gross block | 4,575 | 4,249 | 3,767 | 3,565 | 3,225 | 2,260 |
| Net block | 3,036 | 2,894 | 2,612 | 2,602 | 2,439 | 1,627 |
| Capital work in progress | 221 | 327 | 533 | 417 | 405 | 121 |
| Investments | 3,580 | 3,105 | 1,708 | 1,747 | 1,630 | 1,592 |
| Inventories | 1,873 | 1,205 | 1,153 | 819 | 536 | 421 |
| Sundry debtors | 1,406 | 1,667 | 1,331 | 910 | 989 | 840 |
| Cash & bank balances | 574 | 178 | 242 | 64.16 | 137 | 152 |
| Loans & advances | 451 | 486 | 504 | 456 | 403 | 355 |
| Total current assets | 4,305 | 3,536 | 3,230 | 2,249 | 2,065 | 1,768 |
| Total current liabilities | 2,462 | 1,434 | 1,433 | 912 | 899 | 1,305 |
| Net working capital | 1,842 | 2,101 | 1,797 | 1,337 | 1,166 | 463 |
| Total assets | 9,022 | 8,744 | 7,921 | 6,936 | 6,300 | 4,281 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Opening cash | 164 | 229 | 54.28 | 128 | 147 | 0.74 |
| Net cash from operating activities | 1,328 | 549 | 358 | 71.52 | 249 | 34.72 |
| Net cash from investing activities | (318) | (552) | (635) | (435) | (1,165) | (4,383) |
| Net cash from financing activities | (615) | (61.74) | 451 | 290 | 896 | 4,494 |
| Net change in cash | 395 | (64.93) | 175 | (73.41) | (19.03) | 146 |
| Closing cash | 574 | 178 | 242 | 64.16 | 137 | 152 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Growth | ||||||
| Sales growth | -9.5% | +20.4% | +27.5% | +3.1% | +13.7% | - |
| EBITDA growth | -47.2% | +68.4% | +582.3% | -80.3% | -25.7% | - |
| PBT growth | -3.8% | +79.5% | +310.4% | -73.3% | -32.7% | +9997.0% |
| Net income growth | +11.4% | +77.6% | +434.0% | -80.8% | -32.0% | - |
| Revenue CAGR (3Y) | +11.6% | +16.5% | +14.3% | - | - | - |
| EBITDA CAGR (3Y) | +82.4% | +31.3% | -0.1% | - | - | - |
| Profitability & leverage | ||||||
| Net income margin | +14.6% | +13.1% | +8.9% | +2.0% | +11.0% | +19.5% |
| Return on capital employed | +10.8% | +12.3% | +8.3% | +3.6% | +9.8% | +16.2% |
| Return on net worth | +9.0% | +9.8% | +6.5% | +1.3% | +8.0% | +13.9% |
| Debt / equity | 0.13 | 0.17 | 0.24 | 0.27 | 0.15 | 0.04 |
| Long-term debt / equity | 0.05 | 0.05 | 0.08 | 0.11 | 0.05 | 0.00 |
| Interest cover | 27.19 | 14.00 | 25.95 | -114.15 | 19.43 | 0.99 |
| Efficiency & per share | ||||||
| Fixed asset turnover | 1.08 | 1.32 | 1.20 | 1.01 | 1.22 | 1.30 |
| Inventory turnover | 3.11 | 4.48 | 4.45 | 5.09 | 6.99 | 6.98 |
| Debtors turnover | 3.11 | 3.53 | 3.92 | 3.63 | 3.65 | 3.50 |
| EPS (βΉ) | 5.27 | 5.22 | 2.96 | 0.58 | 3.10 | 5.75 |
| Dividend per share (βΉ) | 0.00 | 0.14 | 0.11 | 0.00 | 0.56 | 0.00 |
| Book value per share (βΉ) | 61.34 | 56.27 | 50.74 | 44.09 | 43.20 | 41.23 |
Investments & Acquisitions by Piramal Pharma Solutions
Piramal Pharma Solutions has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Hemmo Pharmaceuticals.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Synthetic peptides are manufactured for research, clinical, and commercial applications. | hemmopharma.com | Mumbai, India | 1979 | Mar 2021 | $105.63M |
Complete acquisition details for Piramal Pharma Solutions
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Piramal Pharma Solutions
2 dated milestones of Piramal Pharma Solutions across 33 years, from founding to its latest funding, stage changes and deals.
- Founded Piramal Pharma Solutions is founded.
- Acquisition Acquires Hemmo Pharmaceuticals.
Competitors of Piramal Pharma Solutions
Piramal Pharma Solutions has 3 listed competitors in our database, 1 of them funded. They include Syngene, Piramal Group and Panacea Biotec.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| syngeneintl.com | 1993 | Bengaluru, India | $85.89M | 5,618 | Provider of contract research and manufacturing services for both small molecules and biologics | |
| piramal.com | 1984 | Mumbai, India | 204 | Multinational conglomerate with diverse interests in Pharma, Financial Services and Real Estate | ||
| panaceabiotec.com | 1984 | Ambala, India | 2,095 | Developer of biosimilars, vaccines and natural products |
Detailed competitors of Piramal Pharma Solutions
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Piramal Pharma Solutions
The website of Piramal Pharma Solutions (piramalpharmasolutions.com) receives about 15.7K visits a month.
- Monthly visits15.7K
▲ 26.8% vs previous month
Websites whose visitors overlap most with Piramal Pharma Solutions. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| piramal.com | 100% | 47K | #586,886 | View details | |
| outsourcing-pharma.com | 78% | View details | |||
| heidelberg-pharma.com | 77% | 3.9K | #1,811,054 | View details | |
| healthbiotech.in | 76% | #12,544,949 | View details | ||
| gmp-compliance.org | 70% | #293,120 | View details | ||
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 9 similar websites and full traffic analytics for Piramal Pharma Solutions
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 9 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Contract & Outsourced Manufacturing
3 companies that operate in the same segment as Piramal Pharma Solutions (Contract & Outsourced Manufacturing) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Industrial components, mould bases, and storage solutions are manufactured globally. | 1986 | Coimbatore, Tamil Nadu, India | USD 28 M | USD 853.09 M | 43 | |
Single- and three-phase transformers are manufactured in Mumbai. | 1993 | Mumbai, Maharashtra, India | USD 114.37 M | 618 | ||
Apparel and clothing are manufactured and exported on contract. | 1979 | Bengaluru, Karnataka, India | USD 400 M | 40,280 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Piramal Pharma Solutions
Complete news archive for Piramal Pharma Solutions
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Piramal Pharma Solutions
Piramal Pharma Solutions was founded in 1988.
Piramal Pharma Solutions is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.
Piramal Pharma Solutions has 5,480 employees.
The primary company behind Piramal Pharma Solutions, Piramal Pharma Limited, reported revenue of βΉ9,161 Cr for FY 2026, down 3% year on year.
Piramal Pharma Solutions, founded in 1988 in Mumbai, India, focuses on providing healthcare solutions, producing pharmaceutical products, producing manufactured goods, and contract production. Serves as a contract manufacturer of pharmaceutical products for industry partners. The company is dedicated to excellence, innovation, and customer satisfaction, ensuring sustainable practices and long-term success in its sectors.
Piramal Pharma Solutions's top competitors include Syngene, Panacea Biotec and Piramal Group.
Yes, Piramal Pharma Solutions is publicly traded on NSE under the ticker symbol PPLPHARMA.
Piramal Pharma Solutions has made 1 acquisition, including Hemmo Pharmaceuticals.
Piramal Pharma Solutions operates through Piramal Pharma Limited.
The legal entities of Piramal Pharma Solutions currently have 11 directors, including Peter D Deyoung, Jairaj Manohar Purandare, Sridhar Gorthi and others.
